PRF Technologies (PRFX) Stock Analysis

What PRF Technologies does

PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.

Key metrics

ETFs linked to PRFX

Broad-market and Healthcare sector ETFs an investor holding PRF Technologies is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PRFX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for PRF Technologies?

PRF Technologies trades under the ticker PRFX on NASDAQ.

Which exchange is PRFX listed on?

PRFX is listed on NASDAQ.

What sector does PRF Technologies operate in?

PRF Technologies is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze PRFX in a portfolio?

PortView shows PRFX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.